Teva to present new Azilect data at MDS congress

Teva is to present new clinical data on its Parkinson's disease therapy at a Movement Disorder Society (MDS) congress later this month.

More than 15 abstracts will be presented by Teva at the forthcoming International Congress of Parkinson's Disease and Movement Disorders in Dublin, with data drawn from ongoing and completed studies of Azilect.

The findings will demonstrate the effects of the drug on motor and non-motor Parkinson's symptoms, both as a monotherapy and when added to an ongoing dopamine agonist regimen.

Meanwhile, new clinical trial results will be reported that compare the safety and tolerability of Azilect against pramipexole in early Parkinson's disease.

Dr Michael Hayden, president of global research and development and chief scientific officer at Teva, said: "We are committed to ongoing collaboration with academia, medical institutions and patient advocacy groups to continue our understanding of the role Azilect may play in the treatment landscape for the Parkinson's disease community."

Last month, the company reported a 25 percent year-on-year sales increase in the first quarter of 2012, while also installing Dr Jeremy Levin as its new chief executive officer.